[1] |
van Cutsem G, Isaakidis P, Farley J, et al. Infection Control for Drug-Resistant Tuberculosis: Early Diagnosis and Treatment Is the Key. Clin Infect Dis, 2016, 62 Suppl 3: S238-243. doi: 10.1093/cid/ciw012.
doi: 10.1093/cid/ciw012
URL
|
[2] |
白雪娟, 刘银萍, 张俊仙, 等. 应用基因芯片直接检测结核病患者各类标本中利福平和异烟肼耐药的价值. 中国防痨杂志, 2019, 41(2):138-144. doi: 10.3969/j.issn.1000-6621.2019.02.004.
doi: 10.3969/j.issn.1000-6621.2019.02.004
|
[3] |
李静, 郁晨蕾, 张阳奕, 等. GeneXpert MTB/RIF联合线性探针检测技术在耐药结核病诊断中的应用研究. 中国防痨杂志, 2021, 43(10): 1102-1106. doi: 10.3969/j.issn.1000-6621.2021.10.022.
doi: 10.3969/j.issn.1000-6621.2021.10.022
|
[4] |
金龙, 田琦, 张宝庆, 等. 荧光PCR熔解曲线法检测耐多药肺结核患者对左氧氟沙星和莫西沙星耐药性的效能研究. 中国防痨杂志, 2022, 44(2): 159-163. doi: 10.19982/j.issn.1000-6621.20210488.
doi: 10.19982/j.issn.1000-6621.20210488
|
[5] |
张俊仙, 吴雪琼. 结核分枝杆菌耐药性检测方法的研究进展. 中国防痨杂志, 2019, 41(2): 227-232. doi: 10.3969/j.issn.1000-6621.2019.02.019.
doi: 10.3969/j.issn.1000-6621.2019.02.019
|
[6] |
赵雁林, 逄宇. 结核病实验室检验规程. 北京: 人民卫生出版社, 2015.
|
[7] |
刘立宾, 王静, 李浩, 等. 三种分子方法检测结核分枝杆菌利福平耐药性的比较. 中华临床感染病杂志, 2020, 13(4): 270-275. doi: 10.3760/cma.j.issn.1674-2397.2020.04.004.
doi: 10.3760/cma.j.issn.1674-2397.2020.04.004
|
[8] |
马岩, 杨晓军, 任振娟, 等. 痰标本基因芯片法检测耐多药肺结核的临床价值. 结核与肺部疾病杂志, 2020, 1(3): 112-116. doi: 10.3969/j.issn.2096-8493.2020.02.004.
doi: 10.3969/j.issn.2096-8493.2020.02.004
|
[9] |
李爱芳, 崔晓利, 康磊, 等. 荧光PCR探针熔解曲线法检测结核分枝杆菌耐药性的价值. 中国防痨杂志, 2020, 42(9): 998-1002. doi: 10.3969/j.issn.1000-6621.2020.09.022.
doi: 10.3969/j.issn.1000-6621.2020.09.022
|
[10] |
Jamieson FB, Guthrie JL, Neemuchwala A, et al. Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. J Clin Microbiol, 2014, 52(6): 2157-2162. doi: 10.1128/JCM.00691-14.
doi: 10.1128/JCM.00691-14
pmid: 24740074
|
[11] |
Nakata N, Kai M, Makino M. Mutation analysis of mycobacterial rpoB genes and rifampin resistance using recombinant Mycobacterium smegmatis. Antimicrob Agents Chemother, 2012, 56(4): 2008-2013. doi: 10.1128/AAC.05831-11.
doi: 10.1128/AAC.05831-11
URL
|
[12] |
宋婧, 车南颖. 结核分枝杆菌耐药机制和检测方法的研究进展. 中国医药导报, 2018, 15(29): 29-34. doi: cnki:sun:yycy.0.2018-29-008.
doi: cnki:sun:yycy.0.2018-29-008
|
[13] |
刘银萍, 王杰, 张俊仙, 等. 对异烟肼与丙硫异烟胺耐药的结核分枝杆菌临床分离株检测及相关基因突变的研究. 中国防痨杂志, 2016, 38(9): 718-721. doi: 10.3969/j.issn.1000-6621.2016.09.005.
doi: 10.3969/j.issn.1000-6621.2016.09.005
|
[14] |
Rivière E, Whitfield MG, Nelen J, et al. Identifying isoniazid resistance markers to guide inclusion of high-dose isoniazid in tuberculosis treatment regimens. Clin Microbiol Infect, 2020, 26(10):1332-1337. doi: 10.1016/j.cmi.2020.07.004.
doi: 10.1016/j.cmi.2020.07.004
URL
|
[15] |
Wengenack NL, Uhl JR, St Amand AL, et al. Recombinant Mycobacterium tuberculosis KatG(S315T) is a competent catalase-peroxidase with reduced activity toward isoniazid. J Infect Dis, 1997, 176 (3): 722-727. doi: 10.1086/514096.
doi: 10.1086/514096
pmid: 9291321
|
[16] |
Brossier F, Boudinet M, Jarlier V, et al. Comparative study of enzymatic activities of new KatG mutants from low- and high-level isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Tuberculosis (Edinb), 2016, 100: 15-24. doi: 10.1016/j.tube.2016.06.002.
doi: 10.1016/j.tube.2016.06.002
URL
|
[17] |
Lempens P, Meehan CJ, Vandelannoote K, et al. Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations. Sci Rep, 2018, 8(1): 3246. doi: 10.1038/s41598-018-21378-x.
doi: 10.1038/s41598-018-21378-x
URL
|
[18] |
姜广路, 黄海荣. 中国结核分枝杆菌表型药物敏感性试验方法标准回顾. 中国防痨杂志, 2016, 38(9): 701-705. doi: 10.3969/j.issn.1000-6621.2016.09.002.
doi: 10.3969/j.issn.1000-6621.2016.09.002
|
[19] |
Wu XQ, Lu Y, Zhang JX, et al. Detection of the mutations in katG 315 and inhA-15 of Mycobacterium tuberculosis strains isolated from Chinese patients. Chin Med J (Engl), 2006, 119(3): 230-233.
|
[20] |
魏淑贞, 赵永, 梁庆福, 等. 福建省耐多药结核分枝杆菌对氟喹诺酮类药物表型耐药与gyrA基因突变特征分析. 中国人兽共患病学报, 2016, 32(10): 876-879. doi: 10.3969/j.issn.1002-2694.2016.010.005.
doi: 10.3969/j.issn.1002-2694.2016.010.005
|